Preoperative versus postoperative docetaxel-cisplatin- fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial

  • N. Fazio
  • , R. Biffi
  • , R. Maibach
  • , S. Hayoz
  • , S. Thierstein
  • , P. Brauchli
  • , J. Bernhard
  • , R. Stupp
  • , B. Andreoni
  • , G. Renne
  • , C. Crosta
  • , R. Morant
  • , A. Chiappa
  • , F. Luca
  • , M. G. Zampino
  • , O. Huber
  • , A. Goldhirsch
  • , F. de Braud
  • , A. D. Roth
  • , U. Pace
  • S. Cenciarelli, S. Pozzi, E. Bertani, S. Mura, K. Lorizzo, G. Di Meglio, D. Ravizza, S. Boselli, M. Matter, M. Richter, S. Monfardini, C. Dittrich, M. Häfner, M. Clemens, Susanne Crowe

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)668-673
Number of pages6
JournalAnnals of Oncology
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2016
Externally publishedYes

ASJC Scopus Subject Areas

  • Hematology
  • Oncology

Keywords

  • Chemotherapy
  • Docetaxel
  • Gastric cancer
  • Neoadjuvant
  • Preoperative
  • TCF
  • Humans
  • Middle Aged
  • Postoperative Period
  • Treatment Outcome
  • Gastrectomy
  • Stomach Neoplasms/drug therapy
  • Disease-Free Survival
  • Perioperative Period
  • Cisplatin/administration & dosage
  • Taxoids/administration & dosage
  • Adolescent
  • Fluorouracil/administration & dosage
  • Adult
  • Neoadjuvant Therapy
  • Aged
  • Adenocarcinoma/drug therapy
  • Antineoplastic Combined Chemotherapy Protocols/administration & dosage

Cite this